drugset / Trial / NCT01192854

An Study of Efficacy and Safety of Clevudine

NCT01192854

Phase 3 Completed 288 enrolled Eisai Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Randomized, double blind parallel group, positive control, multi-center trial. Patients will be randomized at 1:1 ratio in group A or group B

Timeline

Start
2010-02
Primary completion
2011-05
Completion
2011-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Adefovir Unknown 10 mg
Subject Clevudine Small molecule 30 mg